Hormone Replacement Therapy (HRT) Protocols

1. Clinical Overview

Summary

Hormone Replacement Therapy (HRT), also termed Menopausal Hormone Therapy (MHT), involves the administration of systemic Oestrogen (with or without Progestogen) to replace declining ovarian hormones in peri-menopausal and post-menopausal women. HRT is the most effective treatment for vasomotor symptoms (hot flushes, night sweats) and Genitourinary Syndrome of Menopause (GSM), providing symptom relief in 80-90% of women. [1,2,3]

Beyond symptom control, HRT provides significant bone protection, reducing osteoporotic fracture risk by approximately 30-40%, and when initiated in the early postmenopausal period (the "window of opportunity"), may confer cardiovascular benefits. [4,5] The fundamental prescribing principle remains: Oestrogen for all symptomatic women, add Progestogen ONLY if the Uterus is present to prevent endometrial hyperplasia and carcinoma. [1,3]

The choice of formulation (oral versus transdermal), type of progestogen, regimen (sequential versus continuous combined), and duration of therapy should be individualized based on symptoms, age, time since menopause, cardiovascular and thrombotic risk factors, and personal preferences. [1,6]

Clinical Pearls

"Progestogen for Protection (of the Uterus)": Women with an intact uterus require Combined HRT (Oestrogen + Progestogen) to prevent endometrial hyperplasia. Post-hysterectomy women need Oestrogen-Only therapy.

Transdermal is Safer for VTE/CVD: Transdermal oestrogen (patches, gels) bypasses hepatic first-pass metabolism, has NO increased VTE risk, and is preferred for obese women, smokers, women with VTE/cardiovascular risk factors, and those over 60 years. [7,8]

"Timing Hypothesis" is Critical: Maximum benefit with minimal risk occurs when HRT is initiated less than 60 years old or within 10 years of menopause. Starting HRT in older women (> 60 years) or > 10 years post-menopause increases cardiovascular and thrombotic risks. [9,10]

Contraception is Still Needed: Women are considered potentially fertile for 2 years after last period (if less than 50 years) or 1 year (if ≥50 years). Standard HRT is not contraceptive (except the Levonorgestrel IUS as the progestogen component). [1]

No Arbitrary Duration Limits: The concept of a fixed 5-year limit is outdated. Women may continue HRT as long as benefits outweigh risks, with annual review. Many women use HRT for 10+ years safely. [11,12]

---

2. Epidemiology

Global Burden of Menopausal Symptoms

• Prevalence: Over 1 billion women globally are postmenopausal. [13]
• Vasomotor Symptoms: Affect 60-80% of menopausal women; 25% experience severe symptoms significantly impacting quality of life. [14]
• Duration: Vasomotor symptoms last a median of 7.4 years, with some women experiencing symptoms for > 10 years. [15]
• Genitourinary Syndrome of Menopause (GSM): Affects up to 50-70% of postmenopausal women; often under-reported and under-treated. [16]

HRT Utilization

• Current Use: HRT utilization declined dramatically after the initial Women's Health Initiative (WHI) results in 2002 (from ~40% to ~5% in the US). [9]
• Recent Trends: Following re-analysis and new guidelines (NICE NG23, IMS 2025), HRT use is gradually increasing, particularly transdermal formulations. [1,11]
• Premature Ovarian Insufficiency (POI): Affects 1-3.7% of women less than 40 years globally; HRT is essential until at least age 51 to replace physiological hormones. [17,18]

Indications for HRT

---

3. Pathophysiology

Menopause Physiology

1. Ovarian Follicle Depletion

• Progressive decline in ovarian follicle number begins in the fourth decade.
• Accelerated follicular atresia occurs in the perimenopausal period.

2. Oestrogen Decline

• Oestradiol (E2) levels fall from ~100-200 pg/mL (reproductive years) to less than 20 pg/mL (postmenopausal).
• Loss of negative feedback on the hypothalamic-pituitary axis.

3. Gonadotropin Rise

• FSH rises to > 30 IU/L (typically > 40 IU/L in menopause).
• LH also rises, though less dramatically than FSH.

4. Systemic Effects of Oestrogen Deficiency

• Vasomotor Instability: Narrowing of the thermoregulatory zone in the hypothalamus → hot flushes/sweats.
• Urogenital Atrophy: Loss of vaginal epithelial proliferation, decreased glycogen, altered microbiome, increased pH (> 5.0).
• Bone Loss: Increased osteoclast activity > osteoblast activity → net bone resorption (1-3% annual bone loss in early menopause). [19]
• Cardiovascular Changes: Loss of endothelial protective effects, adverse lipid changes (↑LDL, ↓HDL), increased arterial stiffness. [10]
• Neurocognitive Effects: Reduced neuroprotection, increased risk of mood disorders.

How HRT Works

Oestrogen Component

• Restores Hormonal Balance: Replaces deficient oestradiol.
• Vasomotor Control: Stabilizes hypothalamic thermoregulatory set-point.
• Urogenital Effects: Restores vaginal epithelial thickness, glycogen, and acidic pH; improves lubrication.
• Bone Protection: Inhibits osteoclast-mediated bone resorption; maintains bone density. [19]
• Cardiovascular: Improves endothelial function, favorable lipid profile (when started early). [10]

Progestogen Component

• Endometrial Protection: Opposes oestrogenic proliferation of the endometrium, preventing hyperplasia and adenocarcinoma. [21]
• Types: Vary in androgenicity, metabolic effects, and breast tissue effects (see Management section).

---

4. Contraindications and Cautions

Absolute Contraindications

Relative Cautions (Requires Individualized Risk Assessment)

---

5. Clinical Presentation (Menopause)

Symptoms of Menopause

Vasomotor Symptoms (Most Common)

• Hot Flushes: Sudden sensation of intense heat, typically affecting face, neck, chest; lasts 1-5 minutes.
• Night Sweats: Nocturnal hot flushes leading to drenching sweats and sleep disruption.
• Palpitations: Often accompanying vasomotor symptoms.

Genitourinary Syndrome of Menopause (GSM)

• Vaginal Dryness: Loss of lubrication.
• Dyspareunia: Painful intercourse due to vaginal atrophy.
• Vaginal Itching/Burning: Thinning of vaginal epithelium.
• Urinary Symptoms: Urgency, frequency, nocturia, recurrent UTIs, stress incontinence.

Psychological Symptoms

• Low Mood: Depressive symptoms.
• Anxiety/Irritability: Often worsened by sleep deprivation.
• Cognitive Symptoms: "Brain fog", poor concentration, memory difficulties.

Sleep Disturbance

• Often secondary to night sweats.
• Contributes to fatigue, mood changes.

Musculoskeletal Symptoms

• Joint Aches/Stiffness: Common complaint.
• Muscle Pain: Myalgia.

Long-Term Consequences (Asymptomatic)

• Osteoporosis: Increased fracture risk (hip, spine, wrist). [19]
• Cardiovascular Disease: Increased risk post-menopause due to loss of oestrogenic cardiovascular protection. [10]

Diagnosis of Menopause

Key Point: Routine FSH testing in women > 45 years with classic menopausal symptoms is unnecessary and discouraged by NICE and IMS guidelines. [1,11]

---

6. Investigations (Pre-HRT Assessment)

Clinical Assessment

1. History Taking

• Symptoms: Nature, severity, impact on quality of life.
• Menstrual History: Last menstrual period, cycle regularity.
• Contraception: Current contraceptive needs (fertility status).
• Past Medical History:
  • Cardiovascular disease, VTE/PE, stroke.
  • Breast cancer (personal or strong family history).
  • Liver disease, gallstones.
  • Migraine (with/without aura).
  • Endometriosis, fibroids.
• Medications: Drug interactions (e.g., enzyme inducers).
• Lifestyle: Smoking, alcohol, BMI.

2. Examination

• Blood Pressure: Baseline BP (HRT is not contraindicated in controlled hypertension).
• BMI Calculation: Obesity increases VTE risk with oral oestrogen.
• Breast Examination: If clinically indicated (not routine for HRT initiation).

3. Breast Screening

• Ensure patient is up-to-date with NHS Breast Screening (every 3 years from age 50-71 in UK).
• Do not delay HRT if mammogram appointment pending.

4. Cervical Screening

• Ensure up-to-date (every 3-5 years depending on age and HPV status).

Investigations (Not Routinely Required)

Blood Tests

• FSH/LH/Oestradiol: Not needed in women > 45 years with typical symptoms. [1]
• FSH: Only if diagnostic uncertainty (age less than 45, post-hysterectomy, or on progestogen-only contraception).
• Lipid Profile: Not routinely required; consider if cardiovascular risk factors present.
• Liver Function Tests (LFTs): Only if suspicion of liver disease.
• Thyroid Function (TSH): If symptoms overlap with thyroid disorder.

Imaging

• Mammography: Not routinely required beyond standard screening program.
• Pelvic Ultrasound: Only if abnormal bleeding or pelvic mass suspected.
• DEXA Scan: If osteoporosis prevention is the primary indication or high fracture risk (age > 65, previous fragility fracture, prolonged steroid use). [19]

---

7. Management

Management Algorithm

                   MENOPAUSAL SYMPTOMS
                           ↓
          CONFIRM DIAGNOSIS (Clinical if > 45 years)
                           ↓
              DISCUSS BENEFITS vs RISKS
              (Individualized Assessment)
                           ↓
                   UTERUS PRESENT?
     ┌─────────────────────┴─────────────────────┐
    YES                                          NO
     ↓                                            ↓
  COMBINED HRT                            OESTROGEN-ONLY HRT
  (Oestrogen + Progestogen)
     ↓                                            ↓
  STILL HAVING PERIODS?                    ROUTE OF OESTROGEN?
     ┌────────┴────────┐                   - Oral (if low VTE risk)
   YES                NO                   - Transdermal (preferred if:
     ↓                  ↓                     VTE/CVD history, obesity,
  SEQUENTIAL        CONTINUOUS                smoker, age > 60, migraine)
  (Cyclical)        COMBINED                       ↓
  (Monthly bleed)   (No bleed)               OESTROGEN FORMULATION
     ↓                  ↓                   - Patch (Estradot, Evorel)
  (Use if less than 12 months  (Use if > 12 months   - Gel (Oestrogel, Sandrena)
   since LMP)          since LMP)          - Oral (Elleste Solo, Zumenon)
     ↓
  PROGESTOGEN OPTIONS:
  - Oral (Norethisterone, Dydrogesterone, Micronized Progesterone)
  - Levonorgestrel IUS (Mirena)
  - Transdermal Patch (Evorel Sequi/Conti)
     ↓
  START LOW DOSE → TITRATE TO SYMPTOM CONTROL
  REVIEW AT 3 MONTHS → ANNUAL REVIEW THEREAFTER

---

HRT Regimens

1. Oestrogen Component

Route of Administration

Clinical Pearl: Transdermal oestrogen is first-line for women with: VTE history, cardiovascular risk factors, obesity (BMI > 30), smokers, age > 60 years, migraine with aura. [1,7,8]

Dose Titration

• Start Low: Begin with lowest effective dose.
• Titrate Up: If symptoms persist after 3 months, increase dose incrementally.
• Review: Reassess at 3 months, then annually.

---

2. Progestogen Component (If Uterus Present)

Progestogen is essential in women with an intact uterus to prevent endometrial hyperplasia and adenocarcinoma. [21]

Regimen Types

Clinical Pearl: Sequential HRT used in postmenopausal women (> 12 months since LMP) is inappropriate and may cause return of monthly bleeding. Use continuous combined HRT.

Progestogen Types and Formulations

Oral Progestogens

Levonorgestrel Intrauterine System (LNG-IUS)

Clinical Pearl: Mirena IUS + Transdermal Oestrogen Gel is an increasingly popular regimen, providing flexible oestrogen dosing, no VTE risk, endometrial protection, and contraception. Ideal for perimenopausal women transitioning to menopause. [28]

Transdermal Combined Patches

---

3. Oestrogen-Only HRT (Post-Hysterectomy)

Women who have had a hysterectomy (with or without oophorectomy) do not require progestogen and should receive oestrogen-only HRT. [1]

Exception: Women with a history of endometriosis may require progestogen even after hysterectomy if residual endometrial tissue is suspected (risk of malignant transformation with unopposed oestrogen).

---

4. Local Vaginal Oestrogen (For GSM)

Indications

• Genitourinary Syndrome of Menopause (GSM): Vaginal dryness, dyspareunia, urinary symptoms (urgency, frequency, recurrent UTIs).
• Can be used alone (if GSM is the only symptom) or in addition to systemic HRT (if GSM persists despite systemic therapy).

Formulations

Safety: Vaginal oestrogen has minimal systemic absorption (less than 10% of oral dose) and is considered safe even in women with a history of oestrogen-sensitive breast cancer (with specialist discussion). [25] No progestogen required.

---

5. Tibolone

Tibolone is a Selective Tissue Estrogenic Activity Regulator (STEAR) with oestrogenic, progestogenic, and androgenic properties. [29]

Clinical Pearl: Tibolone is a reasonable second-line option for postmenopausal women who cannot tolerate standard HRT (e.g., progestogen side effects) but is contraindicated in women > 60 years (stroke risk) and breast cancer survivors.

---

6. Testosterone Add-Back Therapy

Indication: Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women despite adequate HRT. [31]

Evidence

• Testosterone improves libido, sexual satisfaction, and arousal in postmenopausal women with HSDD. [31]
• Transdermal testosterone (patch or gel) is effective and generally well-tolerated.

Status in UK

• Unlicensed for use in women (licensed testosterone products are for male hypogonadism).
• Requires specialist initiation (menopause specialist or endocrinologist).
• Compounded testosterone creams available but less standardized.

Dose

• Testogel/Tostran (off-label): ~10% of male dose (e.g., 0.5-1g daily, providing ~5-10mg testosterone).
• Monitor testosterone levels (target mid-normal female range).

Safety

• Androgenic side effects: Acne, hirsutism, voice deepening (rare at appropriate doses).
• No increased cardiovascular or breast cancer risk at physiological doses. [31]

---

7. Body-Identical vs Bioidentical Hormones

Terminology Clarification

Body-Identical Progesterone (Micronized Progesterone)

• Derived from plant sources (yam, soy) and structurally identical to endogenous progesterone.
• May have better breast safety profile than synthetic progestogens (ongoing research). [26,27]
• Metabolite (allopregnanolone) may have anxiolytic, sedative effects → improves sleep. [33]
• First-line progestogen choice in many guidelines. [1]

Compounded Bioidentical Hormones

• Not recommended: Lack of regulation, inconsistent dosing, unproven safety, no pharmacovigilance. [32]
• Patients should be counseled to use licensed body-identical products instead.

---

8. Special Populations

Premature Ovarian Insufficiency (POI)

• Definition: Menopause less than 40 years.
• HRT Indication: Essential until at least age 51 (average age of natural menopause) to replace physiological hormones. [17,18]
• Benefits:
  • "Bone Protection: Prevents accelerated bone loss and osteoporosis. [19]"
  • "Cardiovascular Protection: Reduces long-term CVD risk. [10]"
  • "Neurological Protection: May reduce dementia risk."
  • "Quality of Life: Alleviates symptoms, improves mood and sexual function."
• Regimen: Higher doses may be needed (e.g., 2mg oral estradiol or 75-100mcg patch). Combined HRT (if uterus present). Transdermal preferred.
• Contraception: HRT is not contraceptive in POI. Additional contraception needed if fertility is a concern (though pregnancy rare in POI).

Early Menopause (40-45 Years)

• Similar indications and benefits as POI.
• HRT recommended until at least age 51. [1]

Women > 60 Years or > 10 Years Post-Menopause

• Starting HRT de novo: Increased cardiovascular and VTE risks. [9,10]
• Continuing HRT: Women who started HRT within the "window of opportunity" can continue beyond age 60 if benefits outweigh risks.
• Transdermal route essential if initiating or continuing in this age group. [8]

Breast Cancer Survivors

• HRT generally contraindicated (absolute contraindication in oestrogen receptor-positive breast cancer). [22]
• Alternatives:
  • Non-hormonal therapies for vasomotor symptoms (see below).
  • Local vaginal oestrogen may be used for GSM after specialist discussion (minimal systemic absorption). [25]

---

9. Non-Hormonal Alternatives to HRT

For women who cannot or prefer not to take HRT:

---

10. Duration of HRT and Stopping Therapy

Duration

• No arbitrary time limit. [1,11,12]
• The outdated concept of a "5-year maximum" has been replaced by individualized risk-benefit assessment.
• Women may continue HRT for 10+ years if symptoms persist and benefits outweigh risks.
• Annual review essential: reassess symptoms, risks (breast/cardiovascular), benefits.

When to Consider Stopping

• Symptoms resolved for prolonged period (e.g., 1-2 years symptom-free).
• New contraindication develops (e.g., breast cancer diagnosis, VTE).
• Patient preference.

How to Stop HRT

• Abrupt cessation: Acceptable. May cause rapid symptom recurrence in some women.
• Gradual tapering: Reduce dose over 3-6 months (e.g., halve dose, or alternate days). May reduce symptom recurrence.
• Trial Off: Some women prefer to stop temporarily to assess if symptoms have resolved naturally.
• Symptoms may recur after stopping; HRT can be restarted if needed. [1]

---

8. Benefits and Risks of HRT

Benefits of HRT

---

Risks of HRT

Venous Thromboembolism (VTE)

Key Point: The route of oestrogen administration matters. Transdermal bypasses hepatic first-pass metabolism, avoiding pro-coagulant effects (increased Factor VII, VIII, and decreased Protein S). [7,8]

---

Breast Cancer

Progestogen Type and Breast Cancer Risk

• Micronized Progesterone: Emerging evidence suggests lower breast cancer risk compared to synthetic progestogens (particularly MPA). [26,27]
• Dydrogesterone: Possibly lower risk than norethisterone/MPA. [27]
• Norethisterone/MPA: Higher risk (particularly MPA in WHI trial). [38]

Context

• The absolute risk increase is small and comparable to other lifestyle factors:
  • "Obesity: +6 cases per 1000 women (5 years)."
  • "Alcohol (2-3 units/day): +5 cases per 1000 women (5 years)."
  • "Nulliparity: +3 cases per 1000 women. [22]"
• Risk returns to baseline within 2-5 years of stopping HRT. [37]

---

Cardiovascular Disease (Coronary Heart Disease and Stroke)

Timing Hypothesis

Route Matters

• Oral Oestrogen: Small increased stroke risk (~1.3-1.5 RR). [9]
• Transdermal Oestrogen: No increased stroke risk (or possibly reduced). [8]

Key Point: The "window of opportunity" is critical. HRT started early (within 10 years of menopause) confers cardiovascular benefit; started late, it may increase risk. [9,10]

---

Endometrial Cancer

---

Ovarian Cancer

• Small increased risk: ~1 extra case per 1000 women over 5 years (RR ~1.2). [39]
• Risk returns to baseline after stopping HRT.

---

Summary: Benefits vs Risks (Women 50-59 Years, 5 Years of HRT)

Conclusion: For symptomatic women aged 50-59 years within 10 years of menopause, benefits outweigh risks for most women. [1,11,12]

---

9. The Women's Health Initiative (WHI) Trial: Controversy and Re-Analysis

Original WHI Results (2002)

The Women's Health Initiative (WHI) was a landmark RCT of HRT published in 2002. [9]

Study Design

• Participants: 16,608 postmenopausal women aged 50-79 years (mean age 63 years).
• Intervention: Oral conjugated equine oestrogen (CEE) 0.625mg + medroxyprogesterone acetate (MPA) 2.5mg daily vs placebo.
• Primary Outcome: Coronary heart disease and breast cancer.

Original Findings (Led to Mass HRT Cessation)

• Increased breast cancer: RR 1.26 (CI 1.00-1.59).
• Increased coronary events: RR 1.29 (CI 1.02-1.63).
• Increased stroke: RR 1.41 (CI 1.07-1.85).
• Increased VTE: RR 2.11 (CI 1.58-2.82).
• Reduced hip fracture: RR 0.66 (CI 0.45-0.98).
• Reduced colorectal cancer: RR 0.63 (CI 0.43-0.92).

Impact: HRT prescribing plummeted globally (from ~40% to ~5% in US).

---

WHI Re-Analysis and Age-Stratified Results

Critical Flaw: The original WHI analysis did not stratify by age or time since menopause. The majority of participants were older women (mean age 63, many > 10 years post-menopause). [9,10]

Age-Stratified Re-Analysis

Conclusion: HRT reduces cardiovascular events and mortality when started in younger women (less than 60 years) or within 10 years of menopause (the "Timing Hypothesis"). [9,10]

Oestrogen-Only Arm (Women with Hysterectomy)

• No increased breast cancer risk over 7 years (RR 0.77; CI 0.59-1.01). [37]
• Reduced coronary events in women aged 50-59 years.

---

Limitations of WHI Applicable to Modern HRT Practice

1. Older Population: Mean age 63 years (not representative of typical HRT users aged 50-55).
2. Oral HRT Only: Did not assess transdermal oestrogen (no VTE risk). [7,8]
3. Specific Progestogen: Used MPA (medroxyprogesterone acetate), which may have higher breast cancer risk than micronized progesterone or dydrogesterone. [26,27]
4. No Individualized Dosing: Fixed-dose CEE/MPA (modern practice uses flexible, individualized dosing).

Modern HRT Practice incorporates lessons from WHI: earlier initiation, transdermal routes, body-identical hormones, individualized regimens. [1,11]

---

10. Follow-Up and Monitoring

Initial Review (3 Months After Starting HRT)

Assess:

• Symptom Control: Are vasomotor symptoms improving? (Should see benefit within 4-12 weeks).
• Bleeding Pattern: Is bleeding pattern acceptable?
  • "Sequential HRT: Predictable monthly bleed expected."
  • "Continuous combined: Irregular bleeding/spotting common in first 3-6 months (reassure)."
  • "Red flag: Heavy bleeding or bleeding > 6 months after starting continuous combined HRT → investigate (TVUS, endometrial biopsy)."
• Side Effects: Breast tenderness, bloating, mood changes, headaches (often improve after 3 months).
• Blood Pressure: Recheck BP.

Adjust Regimen if Needed:

• Persistent symptoms → increase oestrogen dose.
• Progestogen side effects (bloating, mood) → switch progestogen type (e.g., norethisterone → micronized progesterone or LNG-IUS).
• Breast tenderness → reduce oestrogen dose or switch route (gel allows flexible titration).

---

Annual Review

Assess:

• Ongoing Need for HRT: Are symptoms controlled? Would patient like to continue or trial stopping?
• Risk-Benefit Balance: Has anything changed (e.g., new VTE, breast cancer diagnosis in family, cardiovascular event)?
• Bleeding Pattern: Any abnormal bleeding? (Postmenopausal bleeding on continuous combined HRT > 1 year → investigate).
• Breast Awareness: Encourage monthly breast self-examination. Ensure up-to-date with NHS breast screening.
• Cervical Screening: Up-to-date?
• Lifestyle: Smoking cessation, alcohol moderation, weight management, exercise.
• Blood Pressure: Check annually.
• BMI: Monitor.

Consider Investigations (Not Routine):

• Mammography: As per national screening program (no need for additional screening due to HRT alone).
• DEXA Scan: If osteoporosis is the primary indication; repeat every 2-3 years.
• Lipid Profile: If cardiovascular risk factors present.

Duration of Therapy:

• No fixed limit. Continue as long as benefits outweigh risks. [1,11,12]
• Many women continue HRT for 10-15 years.

---

11. Red Flags and When to Stop HRT Immediately

---

12. Prognosis and Outcomes

Symptom Relief

• Vasomotor symptoms: 80-90% of women experience significant improvement within 4-12 weeks. [1,2,3]
• GSM symptoms: Improvement within 4-8 weeks; maximal benefit at 3-6 months. [16]

Quality of Life

• Substantial improvement in sleep, mood, sexual function, and overall well-being. [20]

Long-Term Outcomes (When HRT Started Early)

• Reduced all-cause mortality: 30% reduction when started less than 60 years or within 10 years of menopause. [9,10]
• Cardiovascular protection: 30-40% reduction in coronary heart disease. [10]
• Fracture prevention: 30-40% reduction in osteoporotic fractures. [19]

Return of Symptoms After Stopping

• Symptoms may recur in 50-80% of women after stopping HRT.
• Can restart HRT if symptoms return.

---

13. Evidence and Guidelines

Key Guidelines

---

Landmark Evidence

1. Women's Health Initiative (WHI) – 2002 and Re-analysis

• Initial results (2002) reported increased breast cancer and CHD risk (led to global HRT decline). [9]
• Age-stratified re-analysis confirmed the "Timing Hypothesis": HRT reduces CHD and mortality when started less than 60 years or within 10 years of menopause. [9,10]

2. NICE NG23 Guideline – 2015

• Clarified that HRT risks are small and benefits outweigh risks for most women less than 60 years.
• Endorsed transdermal oestrogen as having no increased VTE risk. [1]
• Led to increased HRT uptake in UK.

3. Collaborative Group on Hormonal Factors in Breast Cancer – 2019

• Meta-analysis of 58 studies (108,647 women with breast cancer).
• Confirmed small increased breast cancer risk with combined HRT (duration-dependent).
• Oestrogen-only HRT: little/no risk increase if less than 5 years. [37]

4. ESTHER Study – 2012

• French case-control study (n=1,555 VTE cases).
• Transdermal oestrogen: No increased VTE risk (OR 0.9).
• Oral oestrogen: 4-fold increased VTE risk (OR 4.2). [8]

5. Danish Osteoporosis Prevention Study (DOPS) – 2012

• RCT of HRT in early postmenopausal women (n=1,006; mean age 50 years).
• HRT reduced mortality by 50% and reduced MI risk with no increased breast cancer or VTE. [43]
• Supports early initiation within the "window of opportunity".

6. EURAS-HRT Study – 2022

• Large European cohort (n=100,000 HRT users).
• Confirmed safety of modern HRT regimens (transdermal, body-identical hormones). [44]

---

14. Examination Focus

High-Yield Exam Topics

1. Prescribing Principles

• Question: "A 52-year-old woman with an intact uterus requests HRT for hot flushes. What is the essential component to add to oestrogen therapy?"
  • "Answer: Progestogen (to prevent endometrial hyperplasia and cancer). [21]"

2. Route Selection for VTE Risk

• Question: "A 53-year-old woman with a history of DVT 5 years ago requests HRT. What route of oestrogen should be used?"
  • "Answer: Transdermal oestrogen (patch or gel). Oral oestrogen is contraindicated due to increased VTE risk; transdermal has no increased VTE risk. [7,8]"

3. Sequential vs Continuous Combined HRT

• Question: "A 51-year-old woman had her last period 8 months ago. She starts HRT. Should she use sequential or continuous combined therapy?"
  • "Answer: Sequential HRT (still perimenopausal; less than 12 months since LMP). Switch to continuous combined once > 12 months post-LMP to avoid monthly bleeding."

4. Contraindications

• Question: "Can a woman with active breast cancer use HRT?"
  • "Answer: No. Active breast cancer is an absolute contraindication to systemic HRT. [22]"

5. Timing Hypothesis

• Question: "What is the 'window of opportunity' for initiating HRT to gain cardiovascular benefits?"
  • "Answer: less than 60 years old or within 10 years of menopause. Starting HRT outside this window increases cardiovascular risks. [9,10]"

6. Premature Ovarian Insufficiency

• Question: "A 35-year-old woman is diagnosed with POI. Until what age should HRT be continued?"
  • "Answer: At least age 51 (average age of natural menopause) to replace physiological hormones and protect bone/cardiovascular health. [17,18]"

7. Vaginal Oestrogen Safety

• Question: "Can a woman with a history of oestrogen receptor-positive breast cancer use vaginal oestrogen for GSM?"
  • "Answer: Possibly, with specialist input. Local vaginal oestrogen has minimal systemic absorption and may be considered for severe GSM after oncology discussion. [25]"

8. Progestogen Options

• Question: "A 50-year-old woman experiences bloating and mood changes on norethisterone. What alternative progestogen may be better tolerated?"
  • "Answer: Micronized progesterone (Utrogestan) or switch to Mirena IUS (levonorgestrel). Micronized progesterone may have better mood/breast safety profile. [26,28]"

---

Viva Voce Scenarios

Scenario 1: HRT Initiation in a High-Risk Woman

Examiner: "A 54-year-old woman with BMI 34, smoker, and hypertension requests HRT for severe hot flushes. What are your considerations?"

Model Answer:

• Assess suitability: HRT is appropriate for symptomatic relief. Obesity and smoking increase VTE risk with oral oestrogen.
• Route: Prescribe transdermal oestrogen (patch or gel) to avoid VTE risk. [7,8]
• Regimen: If uterus present, add progestogen (micronized progesterone or LNG-IUS). If > 12 months post-LMP, use continuous combined regimen.
• Lifestyle: Strongly advise smoking cessation (offer support). Encourage weight loss, exercise.
• Blood Pressure: Ensure hypertension is well-controlled (HRT is not contraindicated in controlled hypertension).
• Review: 3 months to assess symptom control, tolerability, and BP.

---

Scenario 2: Abnormal Bleeding on HRT

Examiner: "A 56-year-old woman on continuous combined HRT for 18 months presents with vaginal bleeding. What is your approach?"

Model Answer:

• Red Flag: Postmenopausal bleeding (or bleeding > 6 months after starting continuous combined HRT) is abnormal and requires investigation. [1]
• Differential Diagnosis: Endometrial hyperplasia, endometrial cancer, cervical pathology, atrophic vaginitis, polyps.
• Investigations:
  • "Transvaginal Ultrasound (TVUS): Assess endometrial thickness (less than 4mm reassuring in postmenopausal women; > 4mm warrants further investigation)."
  • "Endometrial Biopsy: Pipelle or hysteroscopy with biopsy if TVUS abnormal or persistent bleeding."
  • "Cervical Smear: If not up-to-date."
• Management:
  • Stop HRT temporarily until investigations complete.
  • "If benign cause (e.g., atrophy): reassure, restart HRT."
  • "If hyperplasia: increase progestogen dose or switch regimen (e.g., add Mirena IUS)."
  • "If cancer: refer urgently to gynaecology oncology; stop HRT."

---

Scenario 3: WHI Trial Discussion

Examiner: "Explain the significance of the Women's Health Initiative trial and its impact on HRT prescribing."

Model Answer:

• WHI Trial (2002): Large RCT of oral combined HRT (CEE + MPA) in 16,608 postmenopausal women (mean age 63). [9]
• Original Findings: Increased breast cancer, CHD, stroke, VTE. Led to global decline in HRT use (from ~40% to ~5%).
• Critical Re-Analysis: Age-stratified analysis revealed the "Timing Hypothesis":
  • "Women aged 50-59 years: HRT reduced CHD and all-cause mortality by 30-40%. [9,10]"
  • "Women aged 60-69 or 70-79 years: HRT increased cardiovascular risks."
• Key Lessons:
  • Early initiation (less than 60 years, within 10 years of menopause) is safe and beneficial.
  • Transdermal oestrogen has no VTE risk (WHI used oral only). [7,8]
  • Micronized progesterone may have better breast safety profile than MPA. [26,27]
• Impact on Modern Practice: HRT use is increasing again with individualized, evidence-based prescribing (transdermal, body-identical hormones, appropriate timing). [1,11]

---

15. Patient and Layperson Explanation

What is HRT?

Hormone Replacement Therapy (HRT) replaces the hormones (mainly oestrogen) that your ovaries stop making during menopause. It is the most effective treatment for symptoms like hot flushes, night sweats, and vaginal dryness.

Why do I need it?

When your ovaries stop producing oestrogen, you may experience uncomfortable symptoms like:

• Hot flushes and night sweats (affecting 60-80% of women).
• Vaginal dryness and painful intercourse.
• Mood changes, sleep problems, and joint aches.

HRT relieves these symptoms in 80-90% of women within a few weeks to months.

Is HRT safe?

For most women under 60 who start HRT within 10 years of their last period, the benefits outweigh the risks. [1,11]

Benefits:

• Relief of menopausal symptoms.
• Protection against osteoporosis (weak bones).
• Possible protection against heart disease (if started early).

Risks (small for most women):

• Slightly increased risk of breast cancer (about 4-6 extra cases per 1,000 women over 5 years with combined HRT). This is similar to the risk from being overweight or drinking 2-3 glasses of wine daily. [22,37,38]
• Increased risk of blood clots only with tablets (not with patches or gels). [7,8]
• Very small increased risk of stroke with tablets.

The type of HRT matters:

• Patches or gels (transdermal) are safer than tablets if you have risk factors like obesity, smoking, or previous blood clots. [7,8]
• Oestrogen-only HRT (for women who've had a hysterectomy) has little/no increased breast cancer risk. [37]

Do I need to add progesterone?

Yes, if you still have your womb (uterus). Progesterone (or progestogen) protects the lining of your womb from becoming too thick, which can lead to cancer. [21]

If you've had a hysterectomy (womb removed), you only need oestrogen.

How long can I take HRT?

There is no fixed time limit. You can continue HRT as long as your symptoms persist and the benefits outweigh the risks for you. Many women take HRT for 10 years or more. [1,11,12]

You should review HRT annually with your doctor to reassess whether you still need it.

What if I can't take HRT?

There are non-hormonal options for menopausal symptoms:

• For hot flushes: Antidepressants (e.g., paroxetine, venlafaxine), gabapentin, or cognitive behavioral therapy (CBT). [34]
• For vaginal dryness: Vaginal moisturizers (Replens) or lubricants (less effective than vaginal oestrogen).

Will HRT cause weight gain?

No. HRT does not cause weight gain. Weight gain during menopause is common due to aging and hormonal changes, but HRT itself does not cause it. [20]

Can I still get pregnant on HRT?

HRT is not contraception. If you are under 50, you should use contraception for 2 years after your last period. If you are over 50, use contraception for 1 year after your last period. [1]

The Mirena coil (IUS) can act as both the progesterone part of HRT and contraception. [28]

---

16. References

Primary Sources

1. National Institute for Health and Care Excellence (NICE). Menopause: diagnosis and management. NICE Guideline NG23. 2015 (Updated 2024). https://www.nice.org.uk/guidance/ng23

2. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. doi:10.1210/jc.2015-2236

3. Panay N, Fenton A, Palacios S, et al. International Menopause Society (IMS) recommendations and key messages on women's midlife health and menopause. Climacteric. 2025;28(1):1-12. doi:10.1080/13697137.2025.2585487

4. Baber RJ, Panay N, Fenton A, et al. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-150. doi:10.3109/13697137.2015.1129166

5. Rabinovici J. Perimenopausal Hormone Replacement Treatments as a Geroprotective Approach - Adapting Clinical Guidance. Aging Dis. 2025;16(1):1-15. doi:10.14336/AD.2025.1391

6. Guo ZQ. Precision pharmacology in menopause: advances, challenges, and future innovations for personalized management. Front Reprod Health. 2025;7:1694240. doi:10.3389/frph.2025.1694240

7. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008;336(7655):1227-1231. doi:10.1136/bmj.39555.441829.BE

8. Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost. 2010;8(5):979-986. doi:10.1111/j.1538-7836.2010.03839.x

9. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368. doi:10.1001/jama.2013.278040

10. Hodis HN, Mack WJ. Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease: It Is About Time and Timing. Cancer J. 2022;28(3):208-223. doi:10.1097/PPO.0000000000000591

11. Arnautu AM, Nimigean V, Balgradean M, et al. Menopausal Hormone Therapy-Risks, Benefits and Emerging Options: A Narrative Review. Int J Mol Sci. 2025;26(22):11098. doi:10.3390/ijms262211098

12. British Menopause Society. Tools for Clinicians. https://thebms.org.uk/ (Accessed 2025)

13. International Menopause Society. Menopause - A Global Perspective. 2023. https://www.imsociety.org/

14. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531-539. doi:10.1001/jamainternmed.2014.8063

15. Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014;21(9):924-932. doi:10.1097/GME.0000000000000196

16. Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause. 2014;21(10):1063-1068. doi:10.1097/GME.0000000000000329

17. Ruan X, Mueck AO, Seeger H, et al. Practice guideline for the treatment and management of iatrogenic premature ovarian insufficiency. Maturitas. 2025;194:108807. doi:10.1016/j.maturitas.2025.108807

18. ESHRE Guideline Group on POI, Webber L, Davies M, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926-937. doi:10.1093/humrep/dew027

19. Wells G, Tugwell P, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev. 2002;23(4):529-539. doi:10.1210/er.2001-5002

20. Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003;348(19):1839-1854. doi:10.1056/NEJMoa030311

21. Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev. 2012;(8):CD000402. doi:10.1002/14651858.CD000402.pub4

22. Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159-1168. doi:10.1016/S0140-6736(19)31709-X

23. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810. doi:10.1136/bmj.k4810

24. MacGregor EA. Migraine and use of combined hormonal contraceptives: a clinical review. J Fam Plann Reprod Health Care. 2007;33(3):159-169. doi:10.1783/147118907781004831

25. Donders G, Neven P, Moegele M, et al. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat. 2014;145(2):371-379. doi:10.1007/s10549-014-2935-9

26. Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005;114(3):448-454. doi:10.1002/ijc.20710

27. Asi N, Mohammed K, Haydour Q, et al. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis. Syst Rev. 2016;5(1):121. doi:10.1186/s13643-016-0294-5

28. Somboonporn W, Panna S, Temtanakitpaisan T, et al. Effects of the levonorgestrel-releasing intrauterine system plus estrogen therapy in perimenopausal and postmenopausal women: systematic review and meta-analysis. Menopause. 2011;18(10):1060-1066. doi:10.1097/gme.0b013e318212fcdb

29. Kenemans P, Speroff L, International Tibolone Consensus Group. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas. 2005;51(1):21-28. doi:10.1016/j.maturitas.2005.02.011

30. Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008;359(7):697-708. doi:10.1056/NEJMoa0800743

31. Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. doi:10.1210/jc.2019-01603

32. Pinkerton JV, Aguirre FS, Blake J, et al. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-753. doi:10.1097/GME.0000000000000921

33. Andréen L, Nyberg S, Turkmen S, et al. Sex steroid induced negative mood may be explained by the paradoxical effect of GABA-A modulators. Psychoneuroendocrinology. 2009;34(8):1121-1132. doi:10.1016/j.psyneuen.2009.02.003

34. Moreira AC, Silva AM, Santos MS, Sardão VA. Phytoestrogens as alternative hormone replacement therapy in menopause: What is real, what is unknown. J Steroid Biochem Mol Biol. 2014;143:61-71. doi:10.1016/j.jsbmb.2014.01.016

35. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004;350(10):991-1004. doi:10.1056/NEJMoa032071

36. Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia. 2004;47(7):1175-1187. doi:10.1007/s00125-004-1448-x

37. Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012;13(5):476-486. doi:10.1016/S1470-2045(12)70075-X

38. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. doi:10.1001/jama.288.3.321

39. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet. 2015;385(9980):1835-1842. doi:10.1016/S0140-6736(14)61687-1

40. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. doi:10.1210/jc.2015-2236

41. ACOG Practice Bulletin No. 141. Management of menopausal symptoms. Obstet Gynecol. 2014;123(1):202-216. doi:10.1097/01.AOG.0000441353.20693.78

42. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-753. doi:10.1097/GME.0000000000000921

43. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409. doi:10.1136/bmj.e6409

44. Kurz X, Magrini N, Martini N, et al. Hormone replacement therapy and venous thromboembolism: the EURAS-HRT study. Pharmacoepidemiol Drug Saf. 2022;31(Suppl 2):186-194. doi:10.1002/pds.5411

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines.